The purpose of this study is to determine the efficacy and safety of levofloxacin combined with endovascular thrombectomy in treating acute ischemic stroke due to large vessel occlusion of anterior circulation.
Age 18-75 years.
Patients with clinically confirmed acute ischemic stroke within 24 hours after onset, CTA or DSA confirmed anterior circulation large vessel occlusion (ICA, M1/proximal M2 segment of MCA, tandem lesions), met the current guidelines for emergency endovascular interventional therapy, and underwent emergency thrombectomy.
mRS≤1 before stroke onset.
Signed and dated informed consent is obtained.
Patients with contraindications to emergency thrombectomy;
The head CT showed large facial cerebral infarction;
Patients using glucocorticoids, antiarrhythmic drugs (class I and class III antiarrhythmic drugs: quinidine, procaine amine, lidocaine, phenytoin sodium, verapamil, etc.), and quinolones within 14 days;
Patients with other diseases that may aggravate adverse drug reactions, such as ventricular arrhythmias, prolonged QT interval (male: QTc>430ms, female: QTc>450ms), severe cardiac insufficiency (NYHA functional grade ≥ III), myasthenia gravis, peripheral neuropathy, seizures, tendon-related diseases, severe immune system-related diseases, hematological diseases, active hepatitis or cirrhosis, serious respiratory diseases;
Parallel
Levofloxacin
DrugLevofloxacin is a quinolone antibiotics and newly identified neuro-protective agent.Endovascular thrombectomy is one of the treatments for acute ischemic stroke.
Levofloxacin simulant
DrugLevofloxacin simulant is placebo.Endovascular thrombectomy is one of the treatments for acute ischemic stroke.
National Institute of Health stroke scale (NIHSS) after 3 days of Levofloxacin/simulant treatment
National Institute of Health stroke scale (NIHSS) ranged from 0 to 42, a low value represents a better outcome.
NIHSS at discharge/7 days
National Institute of Health stroke scale (NIHSS) ranged from 0 to 42, a low value represents a better outcome.
Hemorrhagic transformation and symptomatic intracranial hemorrhage
defined by computed Tomography (CT) brain scan suggested bleeding, accompanied by an increase in National Institute of Health stroke scale (NIHSS) score of ≥4 points.
Infarct volume after 3 days of Levofloxacin/simulant treatment
assessed by magnetic resonance imaging brain scan
Modified rankin scale (mRS) score at 30 days
Modified Rankin Scale (mRS), ranged from 0 to 6, a low value represents a better outcome.
mRS score at 90 days
Modified Rankin Scale (mRS), ranged from 0 to 6, a low value represents a better outcome.
Click on the lead sponsor to view all of their trials.
Yi Yang
Lead sponsor
The First Hospital of Jilin University
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
